PharmTech Poll Results: Outsourced or In-house? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Poll Results: Outsourced or In-house?


The question:

If your company uses contract service providers and manufacturers, which function(s) do you typically keep in-house?

Your responses:

  • Discovery research (1 response)
  • Preclinical animal research
  • ADME-tox work
  • Formulation development (1 response)
  • Process development (1 response)
  • Clincial-scale manufacturing through Phase I
  • Clinical-scale manufacturing through Phase II
  • Clinical-scale manufacturing through Phase III
  • Clinical trials
  • Scale-up to commercial manufacturing (2 responses)
  • Commercial-scale manufacturing (2 responses)
  • Fill-finish
  • Other

Do you have any comments on this poll, or would you like to submit your vote? Email us at ptweb@advanstar.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here